JPM vs SSBI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
SSBI presents a contradictory profile characterized by a weak Piotroski F-Score of 3/9, indicating poor financial health, and a missing Altman Z-Score. While the stock trades below its Graham Number ($18.43) and Book Value (P/B 0.92), it is significantly overpriced relative to its growth-based Intrinsic Value of $7.07. Massive YoY revenue growth (327.5%) suggests a non-organic event or accounting shift, while a bearish technical trend (10/100) and low ROA (0.66%) signal underlying instability. The valuation is attractive from a defensive standpoint, but the fundamental health is concerning.
Compare Another Pair
Related Comparisons
JPM vs SSBI: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Summit State Bank (SSBI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.